Acadia Pharma GAAP EPS of $0.10 beats by $0.05, revenue of $205.83M misses by $2.75M
by
Contributor since / Followers
Contributor since / Followers
7 months ago
- Acadia Pharma press release (NASDAQ:ACAD): Q1 GAAP EPS of $0.10 beats by $0.05.
- Revenue of $205.83M (+73.8% Y/Y) misses by $2.75M.
-
Full Year 2024 Financial Guidance
Acadia is reiterating all of its 2024 guidance provided on February 27, 2024.
- DAYBUE net product sales guidance in the range of $370 to $420 million.
- NUPLAZID net product sales guidance in the range of $560 to $590 million.
- R&D expense in the range of $305 to $325 million.
- SG&A expense in the range of $455 to $480 million.